Back

The impact of dapagliflozin on left atrial functions in non-diabetic atrial fibrillation patients in the early post-cryoablation period

1 April 2025 (08:00 - 14:15)
Organised by: Logo
Congress Presentation Part of: Poster session 3: clinical management of arrhythmias Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Sukran Nur Sanli

Istanbul University Cerrahpasa Faculty of Medicine, Istanbul (Turkiye)

139 More presentations in this session

Presentation thumbnail
The relationship between left atrial electroanatomical voltage mapping and CMR-based fibrosis for enhanced preplanning in atrial fibrillation ablation
Doctor Z. Dadon (Jerusalem, IL)
Abstract Slides Video
Presentation thumbnail
Cardiac sympathetic denervation for different cardiovascular indications - the experience of two referral centers
Doctor A. Zienciuk-Krajka (Gdansk, PL)
Abstract
Presentation thumbnail
Practicing physicians perception of feasibility and usefulness of quality indicators of treatment for atrial fibrillation
Doctor J. Simic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Risk of left atrial thrombus in patients undergoing catheter ablation for atrial fibrillation and atrial flutter
Assistant Professor F. Guerra (Ancona, IT)
Abstract Slides Video
Presentation thumbnail
Clustering analysis of left atrial smax patterns: predicting atrial fibrillation termination and associations with key clinical factors
Mr J. Huh (Seoul, KR)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3: clinical management of arrhythmias

The Event

Event poster

EHRA 2025

1 April 2025 08:00 CET
You may be interested in
thumbnail
Congress Presentation
The impact of dapagliflozin on left atrial functions and recurrence in non-diabetic patients in the early post-cryoablation period
thumbnail
Congress Presentation
SGLT2 inhibitors and the risk of atrial fibrillation recurrence within one year after radiofrequency ablation
thumbnail
Congress Presentation
Sodium-glucose cotransporter 2 inhibitors are more effective than dipeptidyl peptidase 4 inhibitors in preventing mid-term recurrence after atrial fibrillation ablation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources